<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230626058588N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-08-12</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>Investigating and comparing effect of low dose Atropine and minus lens therapy on intermittent exotropia.</public_title>
      <acronym></acronym>
      <scientific_title>Investigating and comparing the effect of 0.05%Atropine with minus lens therapy method on angle and control of deviation in children with intermittent exotropia.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-07-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>42</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/70963</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The randomization method is done in a simple way with individual units and computer software is used in this randomization. The sequence of randomization is given according to a table in the text of the proposal. To assign labels A and B to the intervention group of low-dose atropine and treatment with negative glasses, a coin toss lottery was used, and group B was determined as the intervention group (use of drops) and group A was determined as the intervention group of using glasses.</study_design>
      <phase>3</phase>
      <hc_freetext>Intermittent exotropia.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Atropine 0.05% is an anticholinergic drug and the first intervention. In order to process this drop, we dilute 0.5% atropine made by Sina Daru Company 10 times with artificial tears. In fact, 1 ml of this drop is combined with 10 ml of artificial tear drops in a special container and given to patients. Parents are asked to put one drop of 0.05% atropine in each eye every day in the afternoon and within a certain time. Parents are taught how to put drops in each eye. Intervention 2: Intervention group: In the treatment with glasses, it will be prescribed based on the lowest power of the negative lens that will lead to the control and reduction of the angle of the deviation. First, the amount of negative lens power equal to 0.5 diopters is placed in front of the eyes, and if the deviation is still not in the controlled state, the amount of negative lens power is increased with steps of 0.25 diopters until the deviation is controlled. The value of the obtained number is added with the amount of spherical refractive error calculated from cyclorefraction and the final lens power is prescribed. If it is observed in the follow-up sessions that the deviation is not properly controlled, the power of the negative lens is increased.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The data of the participating in the study can be shared after de-identifying the people, which is provided to the requester through a SPSS file.

When:
The access period starts 6 months after the results are published.

To whom:
It will be available only to researchers working in academic and scientific institutions.

Conditions:
Only in order to check the correctness of the data and analyze them, they can be approved by researchers or scientific institutions.

Where to obtain:
Farzaneh Dehghanian Nasrabadi, Mobile number: 0098 9133609451, Gmail: Fdehghanian1991@gmail.com

How to obtain:
After sending an e-mail by a researcher or a person from a scientific and university institution to the mentioned e-mail address and after its verification by Mrs. Dehghanian, these data can be obtained.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Farzaneh Dehghanian Nasrabadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Rehabilitation school of Iran University of Medical Sciences, Madadkaran St, Madar square, Mirdamad Ave</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1545913487</zip>
        <telephone>+98 21 2222 7124</telephone>
        <email>Fdehghanian1991@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Farzaneh Dehghanian Nasrabadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Rehabilitation school of Iran University of Medical Sciences, Madadkaran St, Madar square, Mirdamad Ave</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1545913487</zip>
        <telephone>+98 21 2222 7124</telephone>
        <email>Fdehghanian1991@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Full term children with intermittent exotropia.</inclusion_criteria>
      <agemin>2 years</agemin>
      <agemax>8 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Unilateral or bilateral amblyopia
history of epilepsy or seizures and asthma
history of drug sensitivity
history of strabismus surgery
presence of vertical deviation more than 5 prisms
unwillingness to continue this study</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>H50.34</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Intermittent alternating exotropia</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Atropine 0.05% is an anticholinergic drug and the first intervention. In order to process this drop, we dilute 0.5% atropine made by Sina Daru Company 10 times with artificial tears. In fact, 1 ml of this drop is combined with 10 ml of artificial tear drops in a special container and given to patients. Parents are asked to put one drop of 0.05% atropine in each eye every day in the afternoon and within a certain time. Parents are taught how to put drops in each eye.</i_keyword>
      <i_keyword>Intervention group: In the treatment with glasses, it will be prescribed based on the lowest power of the negative lens that will lead to the control and reduction of the angle of the deviation. First, the amount of negative lens power equal to 0.5 diopters is placed in front of the eyes, and if the deviation is still not in the controlled state, the amount of negative lens power is increased with steps of 0.25 diopters until the deviation is controlled. The value of the obtained number is added with the amount of spherical refractive error calculated from cyclorefraction and the final lens power is prescribed. If it is observed in the follow-up sessions that the deviation is not properly controlled, the power of the negative lens is increased.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Angle of deviation, control of deviation. Timepoint: Before, one month and 3 months after intervention. Method of measurement: Angle of deviation: prism bar and cover test. Control of deviation: 3 and 6 scale criteria.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Stereopsis. Timepoint: Before, one month and 3 months after intervention. Method of measurement: Stereopsis: Titmus.</sec_outcome>
      <sec_outcome>Suppression. Timepoint: Before, one month and 3 months after intervention. Method of measurement: 4 dots Worth test.</sec_outcome>
      <sec_outcome>Accommodation response. Timepoint: Before, one month and 3 months after intervention. Method of measurement: MEM dynamic retinoscopy.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-05-27</approval_date>
        <contact_name>Ethics committee of Iran University of Medical Sciences</contact_name>
        <contact_address>Hemat Highway next to Milad Tower Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
